Johnson & Johnson’s Covid-19 single-shot vaccine was shown to be 66% effective in preventing moderate and severe disease in a global Phase 3 trial, but 85% efficacy against severe disease, the company announced Friday.
Johnson & Johnson’s trials show 66% efficacy in global trial, but 85% efficacy against severe Covid-19 disease